

Supplementary Tables:**Table SI: Recombinant Ebola virus antigens elicit serum antibody reactive with homologous antigens and whole virus^a**

Antigen ^d	Adjuvant	Recombinant antigen ^b			Irradiated Ebola virus ^c		
		Post dose 1	Post dose 2	Post dose 3	Post dose 1	Post dose 2	Post dose 3
GP	GPI-0100 ^e	250	27,858	64,000	<100	1397	3363
GP	ISA-51	<250	6964	16,000	<100	155	580
VP24	GPI-0100	<250	16,000	36,758	<100	<100	<100
VP24	ISA-51	<250	9190	36,758	<100	124	<100
VP40	GPI-0100	2297	147,033	≥ 256,000	<100	37,710	30,271
VP40	ISA-51	758	48,503	≥ 256,000	<100	15,659	30,271
NONE	GPI-0100	<250	<250	<250	<100	<100	<100
NONE	ISA-51	<250	<250	<250	<100	<100	<100

^a ELISA antibody titers expressed as geometric mean of individual animal serum dilutions yielding an OD of 0.2 above background

^b ELISA plates coated with homologous recombinant antigens

^c ELISA plates coated with irradiated Ebola virus

^d 10 µg of each antigen used for immunization by s.c. route

^e 100 µg of GPI-0100 used

Table SII: Summary of ELISA titers from the dose response and adjuvant selection study
 ELISA titers are expressed as the dilution yielding the half maximal absorption value (determined by using a sigmoidal curve fitting algorithm). Homologous antigen preparations (GP or VP40) from the same lots as used for immunizations were used as coating antigens. (ND: titer not determined).